A Significant Step Forward in Neonatal Care
Prolacta Celebrates a Major Breakthrough in NICU Nutrition
Prolacta Bioscience has achieved an important milestone in premature infant nutrition, coinciding with NICU Awareness Month. In 2024, their innovative human milk-based nutritional products have been adopted by more than half of the Level III and Level IV neonatal intensive care units (NICUs) across the United States. This significant progress showcases Prolacta's commitment to supporting the tiniest and most vulnerable newborns—those weighing less than 1250 grams (2.75 pounds). This milestone highlights the crucial role human milk plays in reducing severe health risks like necrotizing enterocolitis (NEC), a serious intestinal condition.
For over 17 years, Prolacta's human milk-based nutritional solutions, created from donor breast milk, have offered a vital alternative to cow milk-based products for the treatment of premature infants. This shift toward human milk is far more than just a passing trend; it reflects a growing understanding among healthcare providers about the essential influence of nutrition on the health and recovery of neonates.
A Community Effort to Support Premature Infants
This announcement aligns with NICU Awareness Month, a time when various organizations—including those advocating for families with premature infants—are working diligently to highlight the standards of nutrition in NICUs. Organizations such as the National Black Nurses Association and the Association of Women's Health, Obstetric and Neonatal Nurses are staunchly endorsing the implementation of human milk-based nutrition as standard practice. Their unified message emphasizes the vital role of human milk in safeguarding the health of preterm infants during their most delicate times.
Insights from Experts
Dr. Melinda Elliott, a neonatologist and the chief medical officer at Prolacta, remarks, "The growing use of our fortifiers and formulas signifies a remarkable advancement in neonatal care, showcasing the crucial role of human milk-based nutrition in ensuring the survival and long-term health of extremely premature infants." This statement resonates with the broader acknowledgment among healthcare professionals regarding the effectiveness of human milk in overcoming the unique challenges faced by preterm infants in NICUs.
Recent studies reveal that one in ten babies are born prematurely, with nearly one million infant deaths occurring worldwide each year, according to the World Health Organization. A recent meta-analysis establishes that preterm infants receiving human milk-based nutritional fortifiers have a 50% lower mortality rate compared to those fed cow milk-based fortifiers. This statistic emphasizes the urgent necessity for hospitals and NICUs to integrate human milk-based products into their feeding strategies.
Clinically Proven Advantages
A wealth of clinical studies supports the numerous advantages linked to human milk-based dietary solutions for critically ill and premature infants. The Exclusive Human Milk Diet (EHMD), which underscores Prolacta's 100% human milk-based fortifiers, has proven to:
- Significantly decrease mortality and morbidity rates among the most vulnerable infants.
- Mitigate the risks associated with necrotizing enterocolitis (NEC).
- Reduce instances of feeding intolerance, a common challenge in NICU care.
- Facilitate appropriate growth rates for premature infants in a controlled setting.
- Lower the chances of bronchopulmonary dysplasia (BPD), a chronic lung ailment often affecting preemies.
- Reduce the occurrence of retinopathy of prematurity (ROP), impacting the eyes of preterm infants.
- Minimize cases of late-onset sepsis, which can severely affect an infant's health.
- Improve long-term neurodevelopmental outcomes.
- Shorten hospital stays in NICUs, promoting cost-effective healthcare solutions.
Conclusion: Advocating for Positive Change
Every September, NICU Awareness Month highlights the crucial services provided by NICUs and their unwavering commitment to caring for medically fragile newborns. Prolacta Bioscience's accomplishments in human milk-based nutrition are a beacon of hope for families with premature infants. As more healthcare providers adopt these products, the landscape of neonatal care is progressively transforming, offering better health outcomes and brighter futures for these tiny patients.
Frequently Asked Questions
What does Prolacta's recent announcement signify?
Prolacta's success indicates that more than 50% of NICUs in the U.S. are now utilizing their human milk-based nutrition products for the care of premature infants, marking a key advancement in neonatal care.
Why is human milk-based nutrition crucial for premature infants?
Human milk is packed with essential nutrients and bioactive components that help reduce the risk of serious conditions, like NEC, and enhance the overall health outcomes for preterm infants.
Which organizations support the use of human milk for premature infants?
A variety of organizations advocate for the use of human milk in NICUs, including the National Black Nurses Association and the Association of Women's Health, Obstetric and Neonatal Nurses.
How does Prolacta's diet compare with cow milk-based products?
Research shows that infants on an Exclusive Human Milk Diet experience lower mortality rates and better health outcomes than those fed with cow milk-based formulas.
What clinically observed benefits exist for premature infants on Prolacta's diet?
Clinical evidence indicates that Prolacta's products can decrease mortality, lower the risk of NEC, promote growth, and enhance long-term neurodevelopmental outcomes.
